KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) EBT Margin (2016 - 2025)

NovoCure's EBT Margin history spans 12 years, with the latest figure at 23.49% for Q4 2025.

  • For Q4 2025, EBT Margin rose 1074.0% year-over-year to 23.49%; the TTM value through Dec 2025 reached 20.79%, up 88.0%, while the annual FY2025 figure was 20.79%, 88.0% up from the prior year.
  • EBT Margin for Q4 2025 was 23.49% at NovoCure, down from 17.96% in the prior quarter.
  • Across five years, EBT Margin topped out at 1.83% in Q1 2022 and bottomed at 42.76% in Q2 2023.
  • The 5-year median for EBT Margin is 19.37% (2021), against an average of 21.05%.
  • The largest annual shift saw EBT Margin tumbled -3998bps in 2023 before it surged 2765bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 19.2% in 2021, then crashed by -32bps to 25.35% in 2022, then dropped by -14bps to 28.8% in 2023, then fell by -19bps to 34.23% in 2024, then surged by 31bps to 23.49% in 2025.
  • Per Business Quant, the three most recent readings for NVCR's EBT Margin are 23.49% (Q4 2025), 17.96% (Q3 2025), and 22.03% (Q2 2025).